Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

北京时间2024年12月03日02时39分，Alector, Inc.（ALEC.us）股票出现波动，股价急速跳水5.02%。截至发稿，该股报2.46美元/股，成交量144.382万股， 换手率 1.47%，振幅6.53%。

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company ...

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Stock futures were mixed on Tuesday as investors assessed the threat of new tariffs from President-elect Donald Trump. Here ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

周二，Morgan Stanley调整了对Alector Inc. (NASDAQ:ALEC)股票的立场，将其评级从持平下调至减持。该公司还大幅下调了目标价格，将其从之前的10.00美元大幅下调至3.00美元。